- Home
- SEAT vs CTNM Comparison
SEAT vs CTNM Comparison
Compare SEAT & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- CTNM
- Stock Information
- Founded
- SEAT 2001
- CTNM 2009
- Country
- SEAT United States
- CTNM United States
- Employees
- SEAT N/A
- CTNM N/A
- Industry
- SEAT Industrial Machinery/Components
- CTNM
- Sector
- SEAT Industrials
- CTNM
- Exchange
- SEAT Nasdaq
- CTNM Nasdaq
- Market Cap
- SEAT 516.2M
- CTNM 453.0M
- IPO Year
- SEAT N/A
- CTNM 2024
- Fundamental
- Price
- SEAT $3.79
- CTNM $18.55
- Analyst Decision
- SEAT Strong Buy
- CTNM Strong Buy
- Analyst Count
- SEAT 9
- CTNM 4
- Target Price
- SEAT $7.22
- CTNM $29.25
- AVG Volume (30 Days)
- SEAT 842.0K
- CTNM 75.3K
- Earning Date
- SEAT 11-07-2024
- CTNM 11-06-2024
- Dividend Yield
- SEAT N/A
- CTNM N/A
- EPS Growth
- SEAT N/A
- CTNM N/A
- EPS
- SEAT 0.08
- CTNM N/A
- Revenue
- SEAT $774,076,000.00
- CTNM N/A
- Revenue This Year
- SEAT $15.91
- CTNM N/A
- Revenue Next Year
- SEAT $8.01
- CTNM N/A
- P/E Ratio
- SEAT $44.70
- CTNM N/A
- Revenue Growth
- SEAT 13.91
- CTNM N/A
- 52 Week Low
- SEAT $3.36
- CTNM $13.27
- 52 Week High
- SEAT $8.80
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- SEAT 44.59
- CTNM N/A
- Support Level
- SEAT $3.89
- CTNM N/A
- Resistance Level
- SEAT $4.24
- CTNM N/A
- Average True Range (ATR)
- SEAT 0.18
- CTNM 0.00
- MACD
- SEAT 0.00
- CTNM 0.00
- Stochastic Oscillator
- SEAT 40.58
- CTNM 0.00
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.